Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Fig. 9 | Journal of Ovarian Research

Fig. 9

From: Narrowing the field: cancer-specific promoters for mitochondrially-targeted p53-BH3 fusion gene therapy in ovarian cancer

Fig. 9

hTC TMRE Cell Line Comparison. p53-Bad* constructs under control of the CMV promoter show no significant difference between any of the cell lines, while all cancer cell lines show significantly higher apoptosis in hTC-controlled p53-Bad* compared with normal BJ cells. For each column n = 3, and the data were analyzed using 2-way ANOVA and Bonferroni’s post-test. Each * corresponds to a P value < 0.001, each # a P value of < 0.01, and each “n” to a non-significant P value when the respective ovarian cancer cell column is compared to the normal cell (BJ) column in the same category with Bonferroni’s post-test

Back to article page